Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial to Evaluate the Efficacy and Safety of TQH3821 Tablets in Patients With Treated Rheumatoid Arthritis
Latest Information Update: 26 Feb 2025
At a glance
- Drugs TQH 3821 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 20 Feb 2025 Status changed from recruiting to discontinued.
- 30 Nov 2023 Number of treatment arms are decreased from 6 to 2 by the removal of TQH3821 300 mg and 400 mg arms.
- 30 Nov 2023 Planned number of patients changed from 204 to 180.